Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
Eur J Haematol
; 112(2): 197-210, 2024 Feb.
Article
en En
| MEDLINE
| ID: mdl-37545132
ABSTRACT
The success of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies has realized a longstanding effort toward harnessing the immune system to fight cancer in a truly personalized fashion. Second generation chimeric antigen receptors (CAR) incorporating co-stimulatory molecules like 4-1BB or CD28 were able to overcome some of the hindrances with initial CAR constructs resulting in efficacious products. Many second-generation CAR-T products have been approved in the treatment of relapsed/refractory hematologic malignancies including multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and acute lymphoblastic leukemia. However, challenges remain in optimizing the manufacturing, timely access, limiting the toxicity from CAR-T infusions and improving sustainability of responses derived with CAR-T therapy. Here, we summarize the clinical trial data leading to approval CAR-T therapies in MM and NHL, discuss the limitations with current CAR-T therapy strategies and review emerging strategies for overcoming these limitations.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Linfoma no Hodgkin
/
Neoplasias Hematológicas
/
Receptores Quiméricos de Antígenos
/
Mieloma Múltiple
Límite:
Humans
Idioma:
En
Año:
2024
Tipo del documento:
Article